Leflunomide Orion (Leflunomide)

The active ingredient, leflunomide, blocks the enzyme dihydroorotate dehydrogenase, which is essential for pyrimidine synthesis. By limiting pyrimidine production, the drug suppresses the proliferation of activated lymphocytes, thereby dampening the autoimmune response that drives joint inflammation.

The dosing regimen for Leflunomide Orion is individualized by the prescribing clinician based on the patient’s clinical status, laboratory values, and tolerance. Physicians determine the appropriate loading and maintenance doses, and any adjustments are made according to therapeutic response and safety monitoring.

Leflunomide Orion is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of known teratogenic risk. Women of childbearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

The most common alternative to leflunomide is methotrexate, another DMARD. Both reduce disease activity, but leflunomide is often chosen when patients cannot tolerate methotrexate’s hepatic effects or when a once‑daily oral regimen is preferred. Methotrexate may have a faster onset, while leflunomide offers a different safety profile, especially regarding liver monitoring.

Leflunomide Orion tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

The medication is taken orally, usually as a tablet swallowed whole with water. It is typically taken once daily, with or without food, as directed by the prescribing physician. Patients should follow the exact schedule and any special instructions provided by their healthcare professional.

Serious adverse events include severe liver injury, bone‑marrow suppression leading to low blood counts, life‑threatening infections, and hypertension. Women who become pregnant while on leflunomide must undergo an accelerated elimination procedure because of the drug’s teratogenic potential.

Leflunomide Orion is contraindicated in pregnant women, women of childbearing potential not using reliable contraception, patients with severe hepatic impairment, active serious infections, and those with known hypersensitivity to leflunomide or any of its excipients.